Coya Therapeutics releases investor presentation on Treg-directed combination therapies for neurodegenerative diseases
PUBT · 8h ago
Share
Listen to the news
- Coya outlined a Treg-directed combination-therapy strategy for neurodegenerative diseases, led by COYA 302 in ALS and frontotemporal dementia.
- ALSTARS Phase 2 ALS study remains active; enrollment completion targeted for 2H 2026; top-line data expected in 1Q 2027.
- FTD program advanced with IND accepted in 1Q 2026; Phase 2a initiation expected in 2H 2026.
- Cash runway estimated into 2H 2027; cash balance of about $50.7 million as of March 31, 2026.
- Dr. Reddy’s partnership includes royalties, up to about $700 million in milestones, and a $10 million strategic investment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved